BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 28523478)

  • 21. Study of a humanized inhibitory anti-platelet glycoprotein VI phage antibody from a phage antibody library.
    Liu Q; Zhang C; Yu L; Shi Y; Zhang L; Peng J; Ji X; Hou M
    Hematology; 2016 Jan; 21(1):60-7. PubMed ID: 26330203
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Glycoprotein (GP) VI dimer as a major collagen-binding site of native platelets: direct evidence obtained with dimeric GPVI-specific Fabs.
    Jung SM; Tsuji K; Moroi M
    J Thromb Haemost; 2009 Aug; 7(8):1347-55. PubMed ID: 19486274
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GSK669, a NOD2 receptor antagonist, inhibits thrombosis and oxidative stress via targeting platelet GPVI.
    Pan G; Chang L; Zhang J; Liu Y; Hu L; Zhang S; Zhang J; Qiao J; Jakopin Ž; Hu H; Dong J; Ding Z
    Biochem Pharmacol; 2021 Jan; 183():114315. PubMed ID: 33152345
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of Glycoprotein VI Clustering by Collagen as a Mechanism of Inhibiting Collagen-Induced Platelet Responses: The Example of Losartan.
    Jiang P; Loyau S; Tchitchinadze M; Ropers J; Jondeau G; Jandrot-Perrus M
    PLoS One; 2015; 10(6):e0128744. PubMed ID: 26052700
    [TBL] [Abstract][Full Text] [Related]  

  • 25. ADPase CD39 Fused to Glycoprotein VI-Fc Boosts Local Antithrombotic Effects at Vascular Lesions.
    Degen H; Borst O; Ziegler M; Mojica Munoz AK; Jamasbi J; Walker B; Göbel S; Fassbender J; Adler K; Brandl R; Münch G; Lorenz R; Siess W; Gawaz M; Ungerer M
    J Am Heart Assoc; 2017 Jul; 6(8):. PubMed ID: 28751543
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding.
    Kleinschnitz C; Pozgajova M; Pham M; Bendszus M; Nieswandt B; Stoll G
    Circulation; 2007 May; 115(17):2323-30. PubMed ID: 17438148
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A microchip flow-chamber system for quantitative assessment of the platelet thrombus formation process.
    Hosokawa K; Ohnishi T; Fukasawa M; Kondo T; Sameshima H; Koide T; Tanaka KA; Maruyama I
    Microvasc Res; 2012 Mar; 83(2):154-61. PubMed ID: 22166857
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of Platelet GPVI Protects Against Myocardial Ischemia-Reperfusion Injury.
    Pachel C; Mathes D; Arias-Loza AP; Heitzmann W; Nordbeck P; Deppermann C; Lorenz V; Hofmann U; Nieswandt B; Frantz S
    Arterioscler Thromb Vasc Biol; 2016 Apr; 36(4):629-35. PubMed ID: 26916731
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Human atheromatous plaques stimulate thrombus formation by activating platelet glycoprotein VI.
    Penz S; Reininger AJ; Brandl R; Goyal P; Rabie T; Bernlochner I; Rother E; Goetz C; Engelmann B; Smethurst PA; Ouwehand WH; Farndale R; Nieswandt B; Siess W
    FASEB J; 2005 Jun; 19(8):898-909. PubMed ID: 15923400
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Constitutive dimerization of glycoprotein VI (GPVI) in resting platelets is essential for binding to collagen and activation in flowing blood.
    Jung SM; Moroi M; Soejima K; Nakagaki T; Miura Y; Berndt MC; Gardiner EE; Howes JM; Pugh N; Bihan D; Watson SP; Farndale RW
    J Biol Chem; 2012 Aug; 287(35):30000-13. PubMed ID: 22773837
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Principal role of glycoprotein VI in alpha2beta1 and alphaIIbbeta3 activation during collagen-induced thrombus formation.
    Lecut C; Schoolmeester A; Kuijpers MJ; Broers JL; van Zandvoort MA; Vanhoorelbeke K; Deckmyn H; Jandrot-Perrus M; Heemskerk JW
    Arterioscler Thromb Vasc Biol; 2004 Sep; 24(9):1727-33. PubMed ID: 15231520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior efficacy of clopidogrel plus acetylsalicylic acid compared with extended-release dipyridamole plus acetylsalicylic acid in preventing arterial thrombogenesis in healthy volunteers.
    Cadroy Y; Thalamas C; Sakariassen K; Boneu B
    Thromb Res; 2005; 116(4):293-300. PubMed ID: 16038713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effect of aspirin and epinephrine on experimentally induced thrombogenesis in dogs. A parallelism between in vivo and ex vivo thrombosis models.
    Roux SP; Sakariassen KS; Turitto VT; Baumgartner HR
    Arterioscler Thromb; 1991; 11(5):1182-91. PubMed ID: 1911705
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Microfluidic assay of platelet deposition on collagen by perfusion of whole blood from healthy individuals taking aspirin.
    Li R; Fries S; Li X; Grosser T; Diamond SL
    Clin Chem; 2013 Aug; 59(8):1195-204. PubMed ID: 23592503
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Snake venom metalloproteinases, crotarhagin and alborhagin, induce ectodomain shedding of the platelet collagen receptor, glycoprotein VI.
    Wijeyewickrema LC; Gardiner EE; Moroi M; Berndt MC; Andrews RK
    Thromb Haemost; 2007 Dec; 98(6):1285-90. PubMed ID: 18064326
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct contributions of glycoprotein VI and alpha(2)beta(1) integrin to the induction of platelet protein tyrosine phosphorylation and aggregation.
    Kamiguti AS; Theakston RD; Watson SP; Bon C; Laing GD; Zuzel M
    Arch Biochem Biophys; 2000 Feb; 374(2):356-62. PubMed ID: 10666318
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complementary roles of glycoprotein VI and alpha2beta1 integrin in collagen-induced thrombus formation in flowing whole blood ex vivo.
    Kuijpers MJ; Schulte V; Bergmeier W; Lindhout T; Brakebusch C; Offermanns S; Fässler R; Heemskerk JW; Nieswandt B
    FASEB J; 2003 Apr; 17(6):685-7. PubMed ID: 12586747
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ex vivo evaluation of anti-GPVI antibody in cynomolgus monkeys: dissociation between anti-platelet aggregatory effect and bleeding time.
    Matsumoto Y; Takizawa H; Nakama K; Gong X; Yamada Y; Tandon NN; Kambayashi J
    Thromb Haemost; 2006 Aug; 96(2):167-75. PubMed ID: 16894460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activation-independent, antibody-mediated removal of GPVI from circulating human platelets: development of a novel NOD/SCID mouse model to evaluate the in vivo effectiveness of anti-human platelet agents.
    Boylan B; Berndt MC; Kahn ML; Newman PJ
    Blood; 2006 Aug; 108(3):908-14. PubMed ID: 16569773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-GPVI nanobody blocks collagen- and atherosclerotic plaque-induced GPVI clustering, signaling, and thrombus formation.
    Jooss NJ; Smith CW; Slater A; Montague SJ; Di Y; O'Shea C; Thomas MR; Henskens YMC; Heemskerk JWM; Watson SP; Poulter NS
    J Thromb Haemost; 2022 Nov; 20(11):2617-2631. PubMed ID: 35894121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.